Table 3 of Ozturk, Mol Vis 2009; 15:1906-1914. Table 3 of Ozturk, Mol Vis 2009; 15:1906-1914.
Table 3. Serum concentrations of VEGF and cytokines in the study groups
| Group 1 (Control) (n=28) |
Group 2 No retinopathy) (n=31) |
Group 3 (Nonproliferative retinopathy) (n=49) |
Group 4 (Proliferative retinopathy) (n=46) |
p value* |
||
|---|---|---|---|---|---|---|
| VEGF (pg/ml) |
M±SD | 100.47±49.66 | 137.29±84.45 | 177.07±119.51 | 169.88±109.12 | 0.04 |
| Mdn | 98.20 | 125.37 | 153.07 | 149.12 | ||
| Range | (32.46–186.93) | (24.30–445.76) | (30.03–547.74) | (31.56–487.02) | ||
| IL-1α (pg/ml) |
M±SD | 13.15±32.40 | 5.31±19.07 | 3.40±12.76 | 99.78±484.66 | 0.24 |
| Mdn | 0 | 0 | 0 | 0 | ||
| Range | (0–136.17) | (0–98.6) | (0–64.15) | (0–3255.24) | ||
| IL-6 (pg/ml) |
M±SD | 4.06±5.29 | 4.01±9.13 | 7.98±19.03 | 23.78±91.55 | 0.74 |
| Mdn | 0 | 0 | 0 | 0 | ||
| Range | (0–16.99) | (0–43.64) | (0–101.18) | (0–564.62) | ||
| IL-8 | M±SD | 36.10±37.92 | 104.76±182.93 | 88.40±115.45 | 110.99±157.96 | 0.29 |
| Mdn | 18.83 | 11.96 | 44.19 | 37.64 | ||
| Range | (6.72–142.62) | (0–697.97) | (0–552.88) | (0–775.42) | ||
| IL-10 (pg/ml) |
M±SD | 17.57±42.93 | 8.13±24.17 | 18.43±42.54 | 42.15±202.57 | 0.31 |
| Mdn | 3.34 | 0 | 0 | 0 | ||
| Range | (0–208.27) | (0–128.61) | (0–220.19) | (0–1362.73) | ||
| MIP-1α (pg/ml) |
M±SD | 10.68±14.92 | 9.63±13.46 | 13.08±21.97 | 169.51±1061.659.15 | 0.4 |
| Mdn | 4.69 | 0 | 6.91 | (0–7212.84) | ||
| Range | (0–64.65) | (0–41.94) | (0–120.24) | |||
| MCP-1 (pg/ml) |
M±SD | 154.42±58.29 | 193.26±103.75 | 192.37±78.54 | 311.61±488.61 | 0.03 |
| Mdn | 159.0 | 167.95 | 195.56 | 226.59 | ||
| Range | (44.29–243.0) | (46.42–434.28) | (0–377.19) | (96.80–3475.76) | ||
| EGF (pg/ml) |
M±SD | 146.60±86.80 | 180.29±129.16 | 169.56±106.92 | 189.18±93.82 | 0.41 |
| Mdn | 147.67 | 152.22 | 150.21 | 172.39 | ||
| Range | (7.94–321.46) | (13.07–551.87) | (8.34–484.07) | (39.28–421.02) |